Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PPM1B | O75688 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899600 | 1.00 | TP53 (0.48) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL594645 | 1.00 | TP53 (0.48) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL594647 | 1.00 | TP53 (0.48) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL28405577 | 0.95 | TP53 (0.53) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL6900183 | 0.95 | TP53 (0.53) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL234644 | 0.95 | TP53 (0.53) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL13011542 | 0.95 | TP53 (0.53) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL1169984 | 0.93 | TP53 (0.52) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL1170182 | 0.93 | TP53 (0.52) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL1169988 | 0.93 | TP53 (0.52) | TP53CYP3A4ALDH1A1PPM1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2017035271-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-8153644-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8115011-B2 | (S)-3-{5-[(1-Pyridin-2-yl-3-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-ylamino}-pyrrolidine-1-carboxylic acid ethyl ester; obesity, type II diabetes mellitus and metabolic syndrome | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8058299-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | RDX, C3AR1, LPXN | TP53 1398/4885CYP3A4 544/4885ALDH1A1 576/4885 |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | TP53 4688/4885CYP3A4 1894/4885ALDH1A1 573/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | TP53 4688/4885CYP3A4 1894/4885ALDH1A1 573/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | TP53 4688/4885CYP3A4 1894/4885ALDH1A1 573/4885 |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C3AR1, LPXN | TP53 1398/4885CYP3A4 544/4885ALDH1A1 576/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | TP53 4688/4885CYP3A4 1894/4885ALDH1A1 573/4885 |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | TP53 2338/4885CYP3A4 2691/4885ALDH1A1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.